Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2015

View Archived Issues

Novel small-molecule inhibitors confirm the involvement of PADI4 in neutrophil trap formation

FRAXA grant to Neurotrope preclinical behavioral studies of bryostatin for fragile X syndrome

AGTC and 4DMT collaborate in AAV-gene therapies for ophthalmic diseases

Curadev partners with Roche on IDO-1 and TDO inhibitors

FDA grants priority review to Adcetris supplemental BLA

FDA assigns obinutuzumab orphan drug status for follicular lymphoma

U.S. orphan drug status conferred on triheptanoin for fatty acid oxidation disorders

Preclinical evaluation of the selective FGFR inhibitor INCB-054828

FP-208, an mTOR inhibitor, shows potential for cancer in preclinical studies

An orally available MKNK1 inhibitor from Bayer

TetraLogic and Merck & Co. to collaborate on phase I trial of birinapant and pembrolizumab

Novel zefrafish model for detecting apoptosis

Euroscreen starts phase II trials of ESN-364 in uterine fibroids and polycystic ovary syndrome

SHAL Technologies receives NCI grant to fund preclinical testing of SH-7139

Uric acid as a novel predictive biomarker in ankylosing spondylitis

Pain Therapeutics regains rights to Remoxy from Pfizer

Nimbus Discovery patents IRAK-4 inhibitors

Pfizer's crizotinib receives FDA breakthrough therapy designation for ROS1-positive NSCLC

Pharmakea discloses autotaxin inhibitors

Astex Therapeutics develops prodrugs of gemcitabine and cytarabine

Olatec Industries patents compound for pain and inflammation

Sanford-Burnham Medical Research Institute patent describes EBI2 modulators

Relmada initiates proof-of-concept study for oral buprenorphine

scPharmaceuticals initiates pivotal trial of furosemide solution for subcutaneous administration

Inovio initiates phase I trial of HBV DNA vaccine INO-1800

Teva makes play for Mylan as Perrigo rejects Mylan proposal

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...